Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AB ScienceABSCF 60 EV-to-EBIT is 34.30 as of Aug. 07, 2026. GuruFocus rates ABSCF with a GF Score™ of 60/100 and a GF Value™ of $1.38 (Modestly Undervalued). The stock has 11 warning signs investors should review. Among 688 Drug Manufacturers companies, AB Science ranks worse than 79.65% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
AB Science's Enterprise Value for the quarter that ended in Dec. 2025 was $106.54 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AB Science's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $2.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AB Science EV-to-EBIT Related Terms
AB Science EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for AB Science's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, AB Science's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AB Science EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AB Science's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where AB Science's EV-to-EBIT falls into.
AB Science's current Enterprise Value is $69.46 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AB Science's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $2.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AB Science (ABSCF) has a EV-to-EBIT of 34.30 as of Aug. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AB Science and its competitors. According to the industry distribution chart, AB Science ranks #548 out of 688 companies in the Drug Manufacturers industry, placing it in the top 79.7%.
Is AB Science's EV-to-EBIT too high?
AB Science's current EV-to-EBIT is 34.30. The Drug Manufacturers industry median EV-to-EBIT is 15.55. AB Science's value of 34.30 is 120.6% above this industry median. Based on the distribution chart, AB Science ranks #548 out of 688 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AB Science has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AB Science's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AB Science ranks #548 out of 688 companies for EV-to-EBIT. This places AB Science in the lower half of its industry. The industry median EV-to-EBIT is 15.55. AB Science's value of 34.30 is 120.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.55, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AB Science's current EV-to-EBIT of 34.30 is 120.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AB Science and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AB Science's current EV-to-EBIT is 34.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AB Science stock overvalued right now?
Based on GuruFocus' analysis, AB Science (ABSCF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.38, compared to a current price of $1.12 — trading 18.8% below its estimated fair value. The current EV-to-EBIT is 34.30 and 120.6% above the Drug Manufacturers industry median of 15.55. AB Science's overall GF Score™ is 60/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For AB Science (ABSCF), the current EV-to-EBIT is 34.30 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AB Science (ABSCF) Overvalued in 2026?
Based on GuruFocus' analysis, AB Science stock appears to be undervalued.
The current stock price of $1.12 is trading 18.8% below its estimated GF Value™ of $1.38.
GuruFocus considers AB Science to be Modestly Undervalued.
Key valuation signals for ABSCF:
EV-to-EBIT: 34.30
GF Value™: $1.38 vs. price of $1.12 (18.8% below fair value)
Industry Position: 120.6% above the Drug Manufacturers median (#548 of 688)
No single metric tells the full story. See the ABSCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.
60GF Score
Get the complete analysis for ABSCF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABSCF has been successfully added to your 
